Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis

Catena, Fausto; Gléhen, Olivier; Yonemura, Yutaka; Sugarbaker, Paul H.; Piso, Pompiliu; Ceresoli, Marco; Montori, Giulia; Ansaloni, Luca

doi:10.1016/j.ejso.2016.03.035

Cited by 38 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last years an increase interest for PC from GC has been motivated by the frequent peritoneal spread and by the poor prognosis of this disease. The results of present study underline the importance to prevent PC in GC to achieve better outcomes as reported also in recent studies and metaanalysis (13)(14)(15)(16)(17).…”

Section: Discussionsupporting

confidence: 86%

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience

Montori

Catena

Fugazzola

et al. 2018

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 86%

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience

Montori

Catena

Fugazzola

et al. 2018

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

show abstract

“…The most attractive use of HIPEC in GC would be in an adjuvant setting after a curative surgical resection in patients with a high risk of peritoneal recurrence (prophylactic HIPEC). Randomized trials and meta-analysis were performed to study the results of prophylactic HIPEC in patients with locally advanced GC and reported that HIPEC was associated with a significant improvement in the survival rate and in peritoneal recurrence (1,6,8,(11)(12)(13).…”

Section: Discussionmentioning

confidence: 99%

Overall and disease-free survival in patients treated with CRS + HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis

Fugazzola

Catena

Montori

et al. 2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

“…Coccolini et al [73] concluded that 2-and 5-year overall survival in patients with free cancer cells without carcinosis is increased by intraperitoneal chemotherapy. Peritoneal lavage further increases these survival rates and also it further decreases the peritoneal recurrence rate.…”

Section: Management Of Primary Gastric Cancer With Positive Peritoneamentioning

confidence: 99%

Gastric cancer: prevention and treatment of peritoneal metastases

Sugarbaker¹

2018

JCMT

View full text Add to dashboard Cite

Gastric cancer is an aggressive malignancy that may metastasize through the bloodstream to the liver, through lymphatics to regional lymph nodes, or by penetration of the peritoneal lining of the stomach to result in seeding of the abdominal and pelvis surfaces. Peritoneal metastases are the most common mode of cancer dissemination. Technologies to prevent or treat peritoneal metastases from advanced gastric cancer are presented in this manuscript. The world's literature, both recent and over the past three decades, was reviewed in order to identify publications that present information regarding gastric cancer peritoneal metastases. Over one dozen randomized controlled trials to test perioperative chemotherapy for prevention of peritoneal metastases were reviewed. All of the trials performed with regional chemotherapy during or shortly after gastrectomy were positive. The clinical data regarding the treatment of peritoneal metastases diagnosed at the time of primary cancer resection or in follow-up were reviewed. Neoadjuvant intraperitoneal and systemic chemotherapy shows that some long-term survivors occur after these treatments were combined with cytoreductive surgery and gastrectomy. Similar treatments are advocated for primary gastric cancer with cytology positive for gastric cancer but no visible implants. Surgery for gastric cancer should be combined with perioperative systemic and regional chemotherapy in order to maximally benefit patients with this disease by reducing the negative impact of peritoneal metastases on survival.

show abstract

Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis

Cited by 38 publications

References 25 publications

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience

Overall and disease-free survival in patients treated with CRS + HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis

Gastric cancer: prevention and treatment of peritoneal metastases

Contact Info

Product

Resources

About